期刊文献+

益气解毒方对ACHN人肾癌干细胞微环境影响的实验研究 被引量:2

Effects of Yiqi Jiedu Fang( 益气解毒方) on Microenviroment of ACHN Human Renal Carcinoma Stem Cells
下载PDF
导出
摘要 目的:观察益气解毒方对人肾癌干细胞微环境的影响,探讨其抗肿瘤机制。方法:建立ACHN人肾癌干细胞裸鼠皮下移植瘤模型,随机分为对照组(生理盐水)和益气解毒方组,连续给药25 d,剥取瘤体计算瘤重及抑瘤率;免疫组织化学方法测定移植瘤组织血管内皮生长因子(VEGF)、转化生长因子-β1(TGF-β1)、基质金属蛋白酶-2(MMP-2)、乏氧诱导因子-1α(HIF-1α)表达。结果:与对照组比较,益气解毒方组移植瘤重量显著下降,抑瘤率为37.1%(P<0.01);益气解毒方组瘤组织VEGF、TGF-β1、MMP-2、TGF-β1蛋白表达的平均光密度值降低(P<0.05)。结论:益气解毒方能够抑制ACHN人肾癌干细胞移植瘤的生长,对肾癌干细胞血管生成环境、细胞外因子环境、细胞外基质环境、乏氧环境等微环境的影响是其抗肿瘤作用机制之一。 Objective: To clarify the effects of Yiqi Jiedu Fang on the microenvironment of human renal car- cinoma stem cells. Methods: The model of ACNH - transplanted tumor was established in nude mice. The mice were randomly divided into control group and Yiqi Jiedu Fang group, the medication lasted for 25 days. The tumor weight and the tumor inhibition rate were calculated. The expressions of VEGF, TGF - f31, MMP -2 and HIF - 1 et were detected by immunohistochemical assay. Results: Compared with the control group, transplanta- tion tumor weight of Yiqi Jiedu Fang group was significantly decreased(P 〈0. 01 ). The light density value of VEGF,TGF - 61, MMP - 2 and HIF - let expressions in ACHN - transplanted tumor of the Yiqi Jiedu Fang group were significantly decreased(P 〈 0. 05 or P 〈 0. 01 ). Conclusion: Yiqi Jiedu Fang can inhibit the growth of ACHN- transplanted tumor, inhibiting VEGF,TGF-β1, MMP- 2 and HIF- 1α expressions is one of the mechanisms of its anti - tumor effect. Key words
出处 《中国中医药科技》 CAS 2017年第4期419-422,共4页 Chinese Journal of Traditional Medical Science and Technology
基金 山西省自然科学基金项目(2013011046-7)
关键词 益气解毒方 肾癌干细胞 微环境 裸鼠 Yiqi Jiedu Fang reanl cancer stem cells microenviroment nude mice
  • 相关文献

参考文献4

二级参考文献49

  • 1万崇华,陈明清,张灿珍,汤学良,孟琼,张晓磬.癌症患者生命质量测定量表EORTC QLQ-C30中文版评介[J].实用肿瘤杂志,2005,20(4):353-355. 被引量:1337
  • 2林建华,张文明,朱维钦,杨滨.骨肿瘤、骨转移癌患者免疫功能变化及临床意义[J].中华骨科杂志,1996,16(8):495-497. 被引量:2
  • 3WeinAJ,郭应禄,周立群译.坎贝尔-沃尔什泌尿外科学[M].9版.北京:北京大学医学出版社,2009:2645-2648.
  • 4魏恩.坎贝尔-沃尔什泌尿外科学[M].9版,北京:北京大学出版社,2009:1668-1669.
  • 5Liou LS, Shi T, Duan ZH, et al. Microarray gene expression profi- ling and analysis in renal cell carcinoma[ J]. BMC Uro1,2004 ,4 (1) :9.
  • 6Wood C, Srivastava P. An adjuvant autologous therapeutic vaccine (HSPPC -96, vitespen)versus observation alone for patients at high risk of recto'fence after nephrectomy for renal cell carcino- ma : a muhicentre, open - label, randomised phase IH trial [ J ]. Lancet ,2008,372 ( 9633 ) : 145 - 154.
  • 7AKIHIKO MA'ISUMOTO, KYOKO I4ARAGUCHI. Immunothera- py against metastatic renal cell carcinoma with mature dendritic cells [ J ]. International Journal of Urology,2007,14:277 - 283.
  • 8Escudier B, Pluzanska A, Koralewski P, et al. Bevacizumab plus interferon alfa- 2a for Treatment of metastatic renal cell carcino- ma : a randomised, double - blind phase 111 trial [ J ]. Lancet,2007, 370(9605 ) :2103 - 2111.
  • 9Grimm O, Perren A, Weng LP, et al. Diffrential nuclear and cyto- plasmec expression of PTEN in normal thyroid tissue, and benign and malignant epithelial thyroid tumors [ J ]. Am J Pathol, 2000, 156 (5) : 1693 - 1700.
  • 10Atimov A, Li C, Gizatullin R, et al. Somatic mutation and homozy- gous deletion of PTEN/MMACI gene of 10q23 in renal cell car- cinoma [ J ]. Anticancer Res, 1.999,19 (50) :3841 - 3846.

共引文献20

同被引文献16

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部